Cargando…
A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy
BACKGROUND: Duchenne muscular dystrophy (DMD) is a severe neuromuscular disorder and is one of the most common muscular dystrophies. There are currently few effective therapies to treat the disease, although many small-molecule approaches are being pursued. Certain histone deacetylase inhibitors (HD...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559456/ https://www.ncbi.nlm.nih.gov/pubmed/33059738 http://dx.doi.org/10.1186/s13395-020-00251-4 |
_version_ | 1783594865328652288 |
---|---|
author | Farr, Gist H. Morris, Melanie Gomez, Arianna Pham, Thao Kilroy, Elisabeth Parker, Elizabeth U. Said, Shery Henry, Clarissa Maves, Lisa |
author_facet | Farr, Gist H. Morris, Melanie Gomez, Arianna Pham, Thao Kilroy, Elisabeth Parker, Elizabeth U. Said, Shery Henry, Clarissa Maves, Lisa |
author_sort | Farr, Gist H. |
collection | PubMed |
description | BACKGROUND: Duchenne muscular dystrophy (DMD) is a severe neuromuscular disorder and is one of the most common muscular dystrophies. There are currently few effective therapies to treat the disease, although many small-molecule approaches are being pursued. Certain histone deacetylase inhibitors (HDACi) have been shown to ameliorate DMD phenotypes in mouse and zebrafish animal models. The HDACi givinostat has shown promise for DMD in clinical trials. However, beyond a small group of HDACi, other classes of epigenetic small molecules have not been broadly and systematically studied for their benefits for DMD. METHODS: We used an established animal model for DMD, the zebrafish dmd mutant strain sapje. A commercially available library of epigenetic small molecules was used to treat embryonic-larval stages of dmd mutant zebrafish. We used a quantitative muscle birefringence assay in order to assess and compare the effects of small-molecule treatments on dmd mutant zebrafish skeletal muscle structure. RESULTS: We performed a novel chemical-combination screen of a library of epigenetic compounds using the zebrafish dmd model. We identified candidate pools of epigenetic compounds that improve skeletal muscle structure in dmd mutant zebrafish. We then identified a specific combination of two HDACi compounds, oxamflatin and salermide, that ameliorated dmd mutant zebrafish skeletal muscle degeneration. We validated the effects of oxamflatin and salermide on dmd mutant zebrafish in an independent laboratory. Furthermore, we showed that the combination of oxamflatin and salermide caused increased levels of histone H4 acetylation in zebrafish larvae. CONCLUSIONS: Our results provide novel, effective methods for performing a combination of small-molecule screen in zebrafish. Our results also add to the growing evidence that epigenetic small molecules may be promising candidates for treating DMD. |
format | Online Article Text |
id | pubmed-7559456 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-75594562020-10-15 A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy Farr, Gist H. Morris, Melanie Gomez, Arianna Pham, Thao Kilroy, Elisabeth Parker, Elizabeth U. Said, Shery Henry, Clarissa Maves, Lisa Skelet Muscle Research BACKGROUND: Duchenne muscular dystrophy (DMD) is a severe neuromuscular disorder and is one of the most common muscular dystrophies. There are currently few effective therapies to treat the disease, although many small-molecule approaches are being pursued. Certain histone deacetylase inhibitors (HDACi) have been shown to ameliorate DMD phenotypes in mouse and zebrafish animal models. The HDACi givinostat has shown promise for DMD in clinical trials. However, beyond a small group of HDACi, other classes of epigenetic small molecules have not been broadly and systematically studied for their benefits for DMD. METHODS: We used an established animal model for DMD, the zebrafish dmd mutant strain sapje. A commercially available library of epigenetic small molecules was used to treat embryonic-larval stages of dmd mutant zebrafish. We used a quantitative muscle birefringence assay in order to assess and compare the effects of small-molecule treatments on dmd mutant zebrafish skeletal muscle structure. RESULTS: We performed a novel chemical-combination screen of a library of epigenetic compounds using the zebrafish dmd model. We identified candidate pools of epigenetic compounds that improve skeletal muscle structure in dmd mutant zebrafish. We then identified a specific combination of two HDACi compounds, oxamflatin and salermide, that ameliorated dmd mutant zebrafish skeletal muscle degeneration. We validated the effects of oxamflatin and salermide on dmd mutant zebrafish in an independent laboratory. Furthermore, we showed that the combination of oxamflatin and salermide caused increased levels of histone H4 acetylation in zebrafish larvae. CONCLUSIONS: Our results provide novel, effective methods for performing a combination of small-molecule screen in zebrafish. Our results also add to the growing evidence that epigenetic small molecules may be promising candidates for treating DMD. BioMed Central 2020-10-15 /pmc/articles/PMC7559456/ /pubmed/33059738 http://dx.doi.org/10.1186/s13395-020-00251-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Farr, Gist H. Morris, Melanie Gomez, Arianna Pham, Thao Kilroy, Elisabeth Parker, Elizabeth U. Said, Shery Henry, Clarissa Maves, Lisa A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy |
title | A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy |
title_full | A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy |
title_fullStr | A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy |
title_full_unstemmed | A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy |
title_short | A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy |
title_sort | novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of duchenne muscular dystrophy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559456/ https://www.ncbi.nlm.nih.gov/pubmed/33059738 http://dx.doi.org/10.1186/s13395-020-00251-4 |
work_keys_str_mv | AT farrgisth anovelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy AT morrismelanie anovelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy AT gomezarianna anovelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy AT phamthao anovelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy AT kilroyelisabeth anovelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy AT parkerelizabethu anovelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy AT saidshery anovelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy AT henryclarissa anovelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy AT maveslisa anovelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy AT farrgisth novelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy AT morrismelanie novelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy AT gomezarianna novelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy AT phamthao novelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy AT kilroyelisabeth novelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy AT parkerelizabethu novelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy AT saidshery novelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy AT henryclarissa novelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy AT maveslisa novelchemicalcombinationscreeninzebrafishidentifiesepigeneticsmallmoleculecandidatesforthetreatmentofduchennemusculardystrophy |